Trial Profile

NEO-RIT - Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced KRAS Wildtype Rectal Cancer (Clinical Stages II and III).

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Panitumumab (Primary)
Indications Rectal cancer
Focus Therapeutic Use
Acronyms NEO-RIT
Sponsors Wissenschaftlicher Service Pharma

Most Recent Events

15 Nov 2017 Results published in the International Journal of Radiation Oncology, Biology, Physics
15 Nov 2017 Status changed from active, no longer recruiting to completed, according to results published in the International Journal of Radiation Oncology, Biology, Physics.
12 Jan 2016 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com